Testing of a new antibody therapy using blood from children with B-cell Non-Hodgkin lymphoma.

Recruiting

• Conditions: 10025320; Non-Hodgkin B-cell lymphoma

• Registration Number: NL-OMON53135
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Diagnosis op B-Non-Hodgkin lymphoma is the inclusion criterium.

Exclusion Criteria

No diagnosis of B-Non-Hodgkin lymphoma.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Our in vitro experiments with patient material will demonstrate whether:<br /><br>1. Our new anti-CD20 monoclonals are more effective in eliminating malignant<br /><br>CD20+ B cells.<br /><br>2. IgA is superior to IgG in eliminating malignant CD20+ B-cells.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Setting up of a qualitative and quantitative assay to measure B-cel depletion<br /><br>using lymphome and blood material from patients.<br /><br>- Determine the working mechanisms of anti-CD20 IgA mediated B-cel depletion<br /><br>(e.g. involvement of which leukocyte type(s) in ADCC). </p><br>